Skip to main content
. Author manuscript; available in PMC: 2015 May 13.
Published in final edited form as: Vaccine. 2014 Mar 26;32(23):2696–2702. doi: 10.1016/j.vaccine.2014.03.046

Fig. 5.

Fig. 5

Morbidity and mortality of immunized mice following challenge with an antigenically distinct strain. B6 mice were vaccinated with 0.3 μg of TIV or TIV+rOv-ASP-1; some mice were boosted three weeks later. Mice were infected i.n. with a lethal dose (400TCID50) of influenza virus PR8, at week 3 after primary (A & B) or booster immunization (C & D). Survival was defined as ≤ 25% weight loss for PR8 infection. Three to five mice in each group. A and C are representative of two experiments with 3–5 mice with similar results. Ten mice/group for B, and 8~9 mice/group for D are the pooled data from the 2 experiments. * p < 0.05.